Summary

for males ages 18-65 (full criteria)
at UCLA
study started
Other James Peck (ucla)

Description

Summary

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Official Title

Behavioral Therapy Development for Methamphetamine Abuse

Keywords

The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care SettingsBehavior Therapymethamphetamine

Eligibility

You can join if…

Open to males ages 18-65

  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

You CAN'T join if...

  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Locations

  • UCLA Medical Center
    Los AngelesCalifornia90024United States
  • UCLA, Integrated Substance Abuse Programs
    Los AngelesCalifornia90024United States
  • UCLA CARE Clinic
    Los AngelesCalifornia90035United States

Lead Scientist

Details

Status
currently not accepting new patients, but might later
Start Date
Sponsor
University of California, Los Angeles
ID
NCT00249678
Phase
Phase 2
Study Type
Interventional
Last Updated